Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2547)	11/2/2018 3:54:18 AM
From: Miljenko Zuanic	of 3559

Again, to repeat here something that is EXTRA NON-ORDINARY for EYLEA: pmprb-cepmb.gc.ca * Eylea had less than 0.1% of the total pharmaceutical market share in the US, the lowest of all PMPRB7 countries.* In UK it is 5.1% or 51X times. For 2016 Medicare Part B , Eylea sale was $2.1B, and in UK was probably less than $400M (where price in UK is ~1/2 of US). Now, US NIH promoted compounding Avastin for AMD/DME (illegal action by government) and capture 65% volume share for AMD (somewhere less for DME), and inflict generic competition where should be none. Still, Trump used Eylea/Lucentis as example of non-competitive drug pricing. IF there is no compounding Avastin, 2016 PartB drug expenditure for Eylea + Lucentis would be ~$9B. There is already ~$6B saving/year from this ILLEGAL government practice. So, IF REGN/Roche is to take legal action against US government, (as they have right to protect their respective IP), as Novartis/Bayer are doing in EU,.....story would be completely different today.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next